The FDA announced plans to hire more than 1,000 staffers and rolled out a pilot communications program that allows drug sponsors to submit short email clarifications to Office of New Drugs reviewers. Agency officials framed the moves as efforts to speed reviews and reduce avoidable delays. The program sets a three-business-day response target for staff clarifications, creating a new operational touchpoint between regulators and sponsors.